Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alpha-DC1 vaccine + poly-ICLC
- Development stage
- Unknown
- Lead developer
- University of Pittsburgh
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Peptides, Vaccines & Immunotherapeutics
- Administration
- Intranodal, Intramuscular
01
Overview
This investigational cancer immunotherapy consists of alpha-type 1 polarized dendritic cells (αDC1) loaded with synthetic peptides for four glioma-associated antigen (GAA) epitopes: EphA2, IL-13Rα2, YKL-40, and gp100. Developed at the University of Pittsburgh by Dr. Frank Lieberman and Dr. Hideho Okada, the vaccine is administered via ultrasound-guided intranodal injection in combination with poly-ICLC (Hiltonol), a synthetic double-stranded RNA that acts as a Toll-like receptor 3 (TLR3) agonist. This combination is designed to induce a robust, tumor-specific CD8+ T-cell response in HLA-A2 positive patients with recurrent malignant gliomas. The treatment protocol includes an initial vaccination series followed by booster phases to maintain the immune response.
- Brand names
- Hiltonol
- Other names
- alpha-type 1 polarized dendritic cell vaccinealpha-type1 polarized dendritic cell vaccinealpha-type-1 polarized dendritic cell vaccineGAA-pulsed alpha-DC1 vaccineDendritic vaccine pulsed with multiple peptides
02
Targets
IFIH1 (MDA5)TCR (T cell antigen receptor complex)TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on alpha-DC1 vaccine + poly-ICLC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alpha-DC1 vaccine + poly-ICLC.